Abbott Laboratories, Novartis, and Grifols have reached a settlement in their long-running legal battle over a patent ...

European equities traded in the US as American depositary receipts were climbing sharply higher late Wednesday morning, rising 1.37% to 1,315.69 on the S&P Europe Select ADR Index. From continental ...

Al Hilal are ready to offer Mohamed Salah a lucrative contract if he wants to leave Europe and play in Saudi Arabia. Manuel Ugarte's tackling for Manchester United against Liverpool, Raul Jimenez ...

MADRID (Reuters) - U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market ...

In the letter, Mason urges the CNMV to consider the benefits to all Grifols shareholders from improved disclosure around several key issues, including: The full text of the letter follows: Comisión ...

European equities traded in the US as American depositary receipts were trending lower late Friday morning, declining 0.43% to 1,306.41 on the S&P Europe Select ADR Index. From continental Europe, the ...

Two new clinics that pay people for their plasma have opened in Fredericton and Saint John, following a location that was ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As global markets navigate a mixed economic landscape marked by declining consumer confidence and fluctuating indices, technology stocks continue to capture attention with their potential for high ...

The Goethe-Institut USA is Germany's offical cultural center with convenient and effective online German courses and internationally recognized language certificates. As the international market ...

Finland handed the defending champion United States its first loss at the 2025 world junior hockey championship as Tuomas Uronen scored in overtime for a 4-3 win on Sunday afternoon. Finnish ...

Spanish plasma-based medicines maker Grifols (MCE: GRF) has announced disappointing top-line data from its Phase III PRECIOSA clinical trial evaluating the potential of long-term albumin treatment ...